Zura Bio Statistics
Total Valuation
Zura Bio has a market cap or net worth of $151.71 million. The enterprise value is $51.90 million.
| Market Cap | 151.71M |
| Enterprise Value | 51.90M |
Important Dates
The next estimated earnings date is Sunday, May 12, 2024, before market open.
| Earnings Date | May 12, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Zura Bio has 43.59 million shares outstanding. The number of shares has increased by 14,392.36% in one year.
| Shares Outstanding | 43.59M |
| Shares Change (YoY) | +14,392.36% |
| Shares Change (QoQ) | -29.47% |
| Owned by Insiders (%) | 59.43% |
| Owned by Institutions (%) | 46.00% |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 2.56 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.97, with zero debt.
| Current Ratio | 4.97 |
| Quick Ratio | n/a |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -126.30% and return on invested capital (ROIC) is -105.58%.
| Return on Equity (ROE) | -126.30% |
| Return on Assets (ROA) | -76.30% |
| Return on Capital (ROIC) | -105.58% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$4.95M |
| Employee Count | 14 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -56.34% in the last 52 weeks. The beta is 0.54, so Zura Bio's price volatility has been lower than the market average.
| Beta (1Y) | 0.54 |
| 52-Week Price Change | -56.34% |
| 50-Day Moving Average | 3.24 |
| 200-Day Moving Average | 4.88 |
| Relative Strength Index (RSI) | 59.20 |
| Average Volume (30 Days) | 286,882 |
Short Selling Information
The latest short interest is 628,327, so 1.44% of the outstanding shares have been sold short.
| Short Interest | 628,327 |
| Short Previous Month | 330,002 |
| Short % of Shares Out | 1.44% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.37 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -62.64M |
| Pretax Income | -60.36M |
| Net Income | -69.24M |
| EBITDA | -60.36M |
| EBIT | -60.36M |
| Earnings Per Share (EPS) | -$2.09 |
Balance Sheet
The company has $99.81 million in cash and no debt, giving a net cash position of $99.81 million or $2.29 per share.
| Cash & Cash Equivalents | 99.81M |
| Total Debt | n/a |
| Net Cash | 99.81M |
| Net Cash Per Share | $2.29 |
| Equity / Book Value | 59.33M |
| Book Value Per Share | 1.36 |
| Working Capital | 80.54M |
Cash Flow
| Operating Cash Flow | -15.05M |
| Capital Expenditures | n/a |
| Free Cash Flow | -15.05M |
| FCF Per Share | -$0.46 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Zura Bio does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -14,392.36% |
| Shareholder Yield | -14,392.36% |
| Earnings Yield | -45.64% |
| FCF Yield | -9.92% |
Analyst Forecast
The average price target for Zura Bio is $16.50, which is 374.14% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $16.50 |
| Price Target Difference | 374.14% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 2 |